STAT

Opinion: We know enough now to act decisively against Covid-19. Social distancing is a good place to start

Waiting and hoping for a miracle as health systems are overrun by Covid-19 is not an option. We need to use the time we are buying with social distancing to…
A pedestrian walks through a deserted corridor in Chapel Hill, N.C., where bars, restaurants, and other businesses have closed to stop the spread of coronavirus.

In a recent and controversial First Opinion, epidemiologist and statistician John Ioannidis argues that we lack good data on many aspects of the Covid-19 epidemic, and seems to suggest that we should not take drastic actions to curtail the spread of the virus until the data are more certain.

He is absolutely right on the first point. The U.S. has done fewer tests per capita so far than almost any rich country in the world. And many critical details of the epidemiology — including the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks